News Releases

Date	Title and Summary	View
Nov 15, 2018	Janssen seeks expanded use of IMBRUVICA®▼ (ibrutinib) in two indications in Europe
Nov 12, 2018	Johnson & Johnson to Participate in the Citi's 2018 Global Healthcare Conference NEW BRUNSWICK, N.J. , Nov. 12, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Citi's 2018 Global Healthcare Conference on Wednesday, December 5 th , at the Lotte New York Palace Hotel in New York City. Joseph J. Wolk , Executive Vice President and Chief Financial
Nov 06, 2018	Johnson & Johnson to Participate in the Credit Suisse 27th Annual Healthcare Conference NEW BRUNSWICK, N.J. , Nov. 6, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13 th , at The Phoenician in Scottsdale, AZ. Scott White , Company Group Chairman, North America Pharmaceuticals will
Nov 01, 2018	Janssen Shows Commitment to Advancing the Science and Treatment of Blood Cancers and Related Conditions With More Than 80 ASH 2018 Data Presentations From Differentiated Oncology and Cardiovascular Portfolios
Oct 30, 2018	U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Oct 29, 2018	Johnson & Johnson Consumer Aligns To Big Goals In Environmental Sustainability, Signs New Plastics Economy Global Commitment NEW BRUNSWICK, N.J. , Oct. 29, 2018 /PRNewswire/ -- Johnson & Johnson Consumer, Inc. today announced the company is joining an ambitious effort to move the world closer to a circular economy in which plastic never becomes waste. Together with the Ellen MacArthur Foundation , the UN Environment
Oct 26, 2018	Court Issues Ruling in ZYTIGA® Patent Infringement Litigation NEW BRUNSWICK, N.J. , Oct. 26, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the United States District Court , District of New Jersey has issued a ruling invalidating all asserted claims of U.S. Patent No. 8,822,438 for ZYTIGA ® (abiraterone acetate).
Oct 23, 2018	Johnson & Johnson Announces Offer to Acquire Ci:z Holdings Co., Ltd. NEW BRUNSWICK, N.J. , Oct. 23, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that they have agreed with Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company"), a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic
Oct 18, 2018	Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2018 NEW BRUNSWICK, N.J. , Oct. 18, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2018 of $0.90 per share on the company's common stock. The dividend is payable on December 11, 2018 to shareholders
Oct 16, 2018	Johnson & Johnson Reports 2018 Third-Quarter Results: NEW BRUNSWICK, N.J. , Oct. 16, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $20.3 billion for the third quarter of 2018, an increase of 3.6% as compared to the third quarter of 2017. Operational sales results increased 5.5%, partially offset by the negative impact of